RZL-012, a New Fat Dissolving Molecule, Tested in Dercum’s Disease Patients – Dermatologic Surgery:
August 2021 –
Volume 47 – Issue 8 – p 1165-1166
Single session injectable therapy for focal fat reduction.
Raziel offers a revolutionary solution for focal fat-reduction with its proprietary
fat-dissolving injectable compound. This one-time, non-surgical treatment caters to both aesthetic and therapeutic needs. Raziel has already signed a commercial licensing agreement for the Chinese market with Fosun Pharma for its first
application submental fat, commonly known as double-chin.
One versatile solution. Three major applications.
Aesthetics
Therapeutics
Pipeline
Raziel is actively advancing a diverse pipeline in the field of non-surgical fat-reduction.
| Development | Phase 01 | Phase 02 | Phase 03 | Registration | Market |
|---|
Global Recognition & Publications
Raziel was selected as The Most Innovative Company of the Yearat AIS 2022 in San Diego
Mode of Action of RZL-012, a New Fat-Reducing Molecule – Dermatologic Surgery:
December 2021 –
Volume 47 – Issue 12 – p 1601-1605
Efficacy and Safety of Tapencarium (RZL-012) in Submental Fat Reduction – Aesthetic Surgery Journal:
June 22, 2023
Tapencarium (RZL-012) for Flank Fat Reduction: A Proof-of-Concept Study – Aesthetic Surgery Journal Open Forum:
Submitted.
Under preparation
Team
Philippe Schaison, Ph.D.
Chairman of the Board
Dr. Schaison is a CEO, CCO and Global President in consumer healthcare, consumer goods & retail sectors across Asia, South America & Europe with experience running a $2.5B+ business growing 17% a year (Allergan), acquiring/integrating a +$2B organization, and successfully leading global organizations. His communication/interpersonal skills & ability to work effectively with boards/senior executives and build/lead high-performance teams has informed all his work. Hired by the Chairman & Board of Directors of Syneron-Candela NA (Irvine, CA), to take a publicly traded company (ELOS) private, Dr. Schaison sold the company to Private Equity firm Apax in July 2017 for $11 a share; a two-fold increase over past trading value (Nov 2016 – $6 a share). Earlier, as Allergan President, US Aesthetic & Dermatology, Dr. Schaison reports to the CEO and led the Facial Aesthetic, Plastic and MedDerm/Skin Medical BU Presidents. He secured market leadership for every single Botox product by leading a 2-pronged model (B2B and B2C) that enabled the organic growth of the $2.5B business by 17% a year and solidified a one-stop shopping approach with the $2.1B acquisition of Kythera. Leading an internal advertising agency, he optimizes advertising cost efficiencies/effectiveness. Before, Dr. Schaison was President, Clarins WW Travel Retail & Regional President, LATAM and MEA. Reporting to the CEO, and leading a $1B+ business, he generated 55% of Clarins’ total net sales & 70% of its EBIT, achieving 28% growth in a single digit market. Earlier, Dr. Schaison served as CEO for Aesthetic Factors. As VP, Global Skin Care for Johnson & Johnson, with P&L responsibility for leading brands, he consistently exceeded financial business plan objectives. As Board Member, Ortho- Neutrogena, he enabled the entrance into the aesthetic market by recommending Colbar’s acquisition. Dr. Schaison earned an MBA from the Hautes Etudes Commerciales, and a Doctorate in Pharmacy from the University Of Paris V.
Alon Bloomenfeld
CEO
Alon served in management and board member positions for many public and private companies. Prior to founding Raziel, he was CFO of Collplant (NASDAQ: CLGN), Biomedix Incubator Ltd. (TASE:BMDX), BrightCom Technologies (acquired by NYSE-traded Flextronics), and financial manager at Libit Signal Processing (acquired by Texas Instruments, NYSE:TXN). Alon holds an MBA and a BA in Accounting and Finance.
Patricia Walker MD, Ph.D.
Chief Medical Officer
Patricia S. Walker, M.D., Ph.D. is a board-certified dermatologist specializing in medical and aesthetic dermatology. She is an industry expert and has served in various leadership roles, including President and head of R&D for Brickell Biotech, Chief Medical Officer for Kythera Biopharmaceuticals, Inc., Executive Vice President and Chief Scientific Officer for Allergan Medical Aesthetics and Vice President and Dermatology Therapeutic Area Head at Allergan. Dr. Walker’s clinical and research work has contributed substantially to the world of dermatology. Over the past 20 years, she has played a key role in the development and approval of key dermatology products including Tazorac®, Botox® Cosmetic, Juvederm™, Hylaform®, Captique®, LAP-BAND®, Inamed® Silicone gel-filled breast implants and Kybella®. Dr. Walker completed her medical degree and dermatology residency training at the University of Iowa College of Medicine. She also completed a research fellowship at the National Institute of Health’s Dermatology Branch.
Eran Blaugrund, Ph.D.
VP R&D
Eran has twenty-five years of drug development experience. He headed the CNS/Pain project leadership group at Teva Pharmaceuticals with accountability for global development and post-approval project activities. Before that, he led pharmacology development of Azilect for treatment of Parkinson’s disease from early development stages to European approval.
Sharon Cohen Vered, Ph.D.
VP CMC
Sharon has over twenty-five years of experience leading drug development (CMC) teams in pharma, both in large multinationals and in startups. Prior roles includes VP CMC at NeuroDerm, CMC at Orasis Pharmaceuticals, and Head of Parenteral Dosage Forms at Teva innovative R&D. She holds a Ph.D. from Tel Aviv University.
Racheli Gueta, Ph.D.
Clinical Development Director
Racheli has a decade of experience in clinical and R&D activities in multi-disciplinary projects in the pharmaceutical and medical device industry. She holds a Ph.D. in structural biology from the Weizmann Institute of Science, Israel
Alon Bloomenfeld
CEO
Alon served in management and board member positions for many public and private companies. Prior to founding Raziel, he was CFO of Collplant (NASDAQ: CLGN), Biomedix Incubator Ltd. (TASE:BMDX), BrightCom Technologies (acquired by NYSE-traded Flextronics), and financial manager at Libit Signal Processing (acquired by Texas Instruments, NYSE:TXN). Alon holds an MBA and a BA in Accounting and Finance.
×
Contact Us
Office:
+972-8-9126940Email:
[email protected]Location:
10 Prof. Menachem Plaut St.,
Rehovot, Israel